Introduction:

Biological treatment is an alternative to manage ulcerative colitis in patients refractory to conventional treatment.

Objective:

To evaluate biological treatment in patients with ulcerative colitis refractory to conventional treatment in a third-level hospital care.

Methods:

Descriptive, retrospective, longitudinal study in patients with ulcerative colitis refractory to conventional treatment and who received biological treatment. The slices were evaluated at three moments: basal state (without biological therapy), at six and twelve months from the beginning of the biological treatment. Descriptive statistics were used to characterize the population in general; subsequently, the off points were described with their respective variables.

Results:

18 patients with a mean age of 41.2 years were included. The evaluations, in a basal state, at six and 12 months; showed the presence of blood in stools and abdominal pain in 94.4%, 22.2%, and,% respectively, hemoglobin concentration >10.5 g/dl in 50%, 83.3%, and 88.9%; serum albumin concentration >3.2 g/dl in 72.2%, 83.3%, and 88.9% and visual endoscopic Mayo scale 38.9%, 33.3%, and 16.7% presented in May 2 and 61.1%, 16.7% and 1.7% in May 3. Histological activity in the baseline evaluation reached a severe level (11.1%), while in assessments at six and 12 months, it reached moderate at 55.6% and 27.8%, respectively.

Conclusions:

Biological therapy in patients with refractory ulcerative colitis improved clinical, biochemical, endoscopic, and histological manifestations. No profound remission of the disease or adverse reactions to treatment were recorded.

        · resumen en Español     · texto en Español | Inglés     · Español ( pdf ) | Inglés ( pdf )